BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17046466)

  • 1. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
    Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
    Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
    Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
    Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.
    Stoneham S; Lennard L; Coen P; Lilleyman J; Saha V
    Br J Haematol; 2003 Oct; 123(1):100-2. PubMed ID: 14510948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.
    Escherich G; Richards S; Stork LC; Vora AJ;
    Leukemia; 2011 Jun; 25(6):953-9. PubMed ID: 21372841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
    Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
    Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
    Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
    BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.
    De Bruyne R; Portmann B; Samyn M; Bansal S; Knisely A; Mieli-Vergani G; Dhawan A
    J Hepatol; 2006 Feb; 44(2):407-10. PubMed ID: 16226335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
    Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
    Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thioguanine versus mercaptopurine in childhood ALL.
    Stanulla M; Schünemann HJ
    Lancet; 2006 Oct; 368(9544):1304-6. PubMed ID: 17046444
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
    Chen L; Yan HX; Liu XW; Chen WX
    Medicine (Baltimore); 2020 May; 99(18):e20082. PubMed ID: 32358392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
    Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
    Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
    Hann I; Vora A; Richards S; Hill F; Gibson B; Lilleyman J; Kinsey S; Mitchell C; Eden OB
    Leukemia; 2000 Mar; 14(3):356-63. PubMed ID: 10720126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?
    Lennard L; Davies HA; Lilleyman JS
    Br J Cancer; 1993 Jul; 68(1):186-90. PubMed ID: 8318412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.
    Lilleyman JS; Lennard L
    Lancet; 1994 May; 343(8907):1188-90. PubMed ID: 7909868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL].
    Hou YJ; Zhao L; Liu XX; Ma YY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):622-6. PubMed ID: 27151041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience.
    Ravikumara M; Hill FG; Wilson DC; Gillett PM; Thomas A; Brown R; Darbyshire PJ; McKiernan PJ
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):535-8. PubMed ID: 16707977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.